CD4 and congestive heart failure: Crucially, CM's immune-reparative potential is unlocked only when antiviral therapy achieves virological suppression, which explains the CD4+ advantage of 163 cells/μL (95% CrI: 3.93–326.46) for CHF + ART regimens.